Rosanna Ricafort is Vice President, senior global program lead of Hematology/Cell Therapy in the Global Drug Development organization at Bristol Myers Squibb. In this role, she is heads a team of executive leaders accountable for ensuring maximization of asset value and impact to patients through orchestration of design and execution of globally integrated program strategies, timelines, and budgets from candidate nomination to successful launch, commercialization, and lifecycle management. She has oversight for 20+ hematology and cell therapy early-, late-stage and in-line assets, including Reblozyl, Breyanzi and Abecma.

Dr. Ricafort has been with BMS since 2015 and has held increasing leadership positions in Immuno-Oncology Research and Development. She was responsible for multiple clinical development programs across solid tumors and hematologic malignancies, including Sprycel, Empliciti, Yervoy, Opdivo, Breyanzi and Abecma. She led the clinical due diligence of Bristol Myers Squibb’s acquisition of Celgene, one of the largest acquisitions in the healthcare industry. Prior to joining BMS, Dr. Ricafort started her industry career at Celgene, where she supported the multiple myeloma franchise, leading clinical studies for Revlimid and Pomalyst, and the successful launch for Revlimid’s NDMM indication.

Dr. Ricafort is a pediatric hematologist/oncologist and blood and marrow stem cell transplant physician by training; she established and directed the Pediatric Blood and Marrow Transplantation Program at Montefiore Medical Center, NY, where she held a faculty appointment for over 10 years. She earned her Medical Doctorate at Mount Sinai School of Medicine and completed her fellowship training in Pediatric Hematology and Oncology at Memorial Sloan-Kettering Cancer Center in New York. She was a research fellow in MSKCC-Sloan Kettering Institute’s Department of Human Genetics and Immunology working on gene transfer and adoptive cellular therapy strategies in the lab of Michel Sadelain, whose pioneering work has revolutionized the field of cell and gene therapy.